

RESULTS OF ENTITLEMENT OFFER AND SHORTFALL OFFER OPEN

Highlights

- Wellnex Entitlement Offer closes with approximately \$3.1 million raised.
- All Wellnex Directors participated in the Entitlement Offer in addition to the Company's major shareholder Homart Pharmaceuticals.
- Approximately \$10.5 million to be placed with sophisticated and professional investors under Shortfall Offer who previously provided advanced commitments.
- **View the resources page for the Shortfall Offer [here](#)**

Wellnex Life Limited (**Wellnex, WNX or Company**) (ASX:WNX) is pleased to announce that the Company's pro-rata non-renounceable entitlement offer, which closed on Tuesday 28 November 2023 (**Entitlement Offer**), has raised approximately \$3.1 million from eligible Wellnex shareholders who subscribed for their entitlements and additional shares under the oversubscription facility.

Subscribers to the Entitlement Offer will receive 1 attaching option (exercisable at \$0.05 and expiring 30 June 2025) for every 3 new shares issued.

Director and Major Shareholding Participation

All of Wellnex's Directors participated in the Entitlement Offer, as did the Company's largest shareholder, Homart Pharmaceuticals.

Shortfall Offer

Approximately 382 million new shares, representing entitlements not taken up by eligible shareholders under the Entitlement Offer, will be offered to sophisticated and professional investors who have provided interest in participating in any potential shortfall (**Shortfall Offer**). The ability to place the shortfall was previously announced on Monday, 13 November 2023.

The Shortfall Offer is now open and will close on Monday, 4 December 2023. The results of the Shortfall Offer are expected to be announced to ASX on Tuesday, 5 December 2023.

View the resources page for the Shortfall Offer [here](#)

Timetable

Event	Date (2023)
Closing date of Entitlement Offer (5.00pm AEDT)	Tuesday, 28 November
Announcement of results of Entitlement Offer	Friday, 1 December
Shortfall bookbuild and determination of allocation under Shortfall Offer	Monday, 4 December
Issue of Entitlement Offer shares and lodgement of Appendix 2A applying for quotation of the shares (12.00pm AEDT)	Tuesday, 5 December
Issue of Shortfall Offer shares and lodgement of Appendix 2A applying for quotation of the shares (12.00pm AEDT)	Wednesday, 6 December
Completion of Pain Away Transaction	By Friday, 8 December

Note: the above timetable is indicative only and subject to change without notice. All dates and times are Australian Eastern Daylight Time.

Additional Information

Further details of the Entitlement Offer and Shortfall Offer, including their effect on the Company, are set out in the prospectus and supplementary prospectus, which were lodged with ASX. The prospectus and supplementary prospectus contain important information including key risks with respect to the Entitlement Offer and Shortfall Offer. This announcement should be read together with the disclosures made in the prospectus and supplementary prospectus.

If you have any questions in relation to the details of the Offer, please contact Reach Markets on +61 3 8080 5975 or investors@reachmarkets.com.au.

Clarification of Typographical Error in 2023 Annual Report

Wellnex refers to its annual report lodged with ASX on 2 November 2023, which contained its audited financial statements for the financial year ended 30 June 2023 (**Financial Statements**).

Wellnex has identified a minor typographical error in Note 15 (*Current liabilities – borrowings*) to the Financial Statements, which contained the following statement (on page 38, under the heading “Trade and debtor facility”):

“amount drawn down [under Wellnex’s \$5.3 million secured revolving trade and debtor facility with Scottish Pacific] as at 30 June 2023: \$4,758,000”

Wellnex clarifies that, consistent with its other disclosures in Note 15 to the Financial Statements, the amount drawn down under the \$5.3 million Scottish Pacific facility as at 30 June 2023 was \$542,000, and the amount undrawn was \$4,758,000.

Accordingly, Wellnex confirms that the statement should be corrected to read:

“amount **undrawn** as at 30 June 2023: \$4,758,000”

The Board has authorised that this document be given to the ASX.

- ENDS -

For further information, please contact:

Reach Markets

P: +61 3 8080 5975

E: investors@reachmarkets.com.au

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently agreed to acquire leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be registered, under the US Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the Securities Act and applicable US state securities laws. This announcement contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Wellnex, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions. You are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the ongoing impact of COVID-19 as well as the military conflict in the Middle East and Ukraine. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Wellnex's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the ongoing impact of COVID-19 as well as the

military conflict in the Middle East and Ukraine, and except as required by law or regulation, none of Wellnex, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking statements are based on information available to Wellnex as at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of Wellnex, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The information in this announcement is in summary form and does not contain all the information necessary to fully evaluate the transaction or investment. It should be read in conjunction with Wellnex's other periodic and continuous disclosure announcements lodged with the ASX. The announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and does not form the basis of any contract or commitment. All persons should consider seeking appropriate professional advice in reviewing this announcement.